pembrolizumab

Ligand id: 7499

Name: pembrolizumab

Classification
Compound class Antibody
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2014), EMA (2015))
International Nonproprietary Names
INN number INN
9798 pembrolizumab
Synonyms
Keytruda® | lambrolizumab | MK-3475
Database Links
Specialist databases
IMGT/mAb-DB 472
Other databases
GtoPdb PubChem SID 187051801
PubChem SID 187051801
Search PubMed clinical trials pembrolizumab
Search PubMed titles pembrolizumab
Search PubMed titles/abstracts pembrolizumab
Wikipedia Pembrolizumab
Comments
Pembrolizumab is the first-in-class, anti-PD-1 antibody to be approved by the US FDA.
Full peptide sequence and disulphide bond information is available from the IMGT/mAb-DB entry for this antibody.

Pembrolizumab is the first immuno-oncology therapeutic to be approved for use in cancers of any tissue type, so long as they express a specific genetic biomarker (i.e. high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumours). This is an important breakthrough, since up until this point FDA approvals, including earlier approvals for pembrolizumab, had always been restricted to certain tissue-specific cancers.